Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M D Ravi

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Indian Pediatrics|November 22, 2000
Pyoderma gangrenosumM D Ravi, N Sanju
Indian Journal of Pediatrics|March 25, 2014
Vaccination Related Pain: Comparison of Two Injection TechniquesG N Girish, M D Ravi
Hospital Pharmacy|September 25, 2024
Chronic Immune Thrombocytopenia Purpura Following COVID-19 Vaccination (ChAdOx1 -nCov-19): A Case Report With OneYear Follow-UpMerrin Mathew, Rovin M Theempalangad, Juny Sebastian, et al.
Intractable & Rare Diseases Research|August 27, 2020
Comprehensive Rare Disease Care model for screening and diagnosis of rare genetic diseases - an experience of private medical college and hospital, South IndiaSathish Raju Nilakantam, Deepa Bhat, M D Ravi, et al.
Vaccine: X|July 28, 2022
Antibody persistence following administration of a hexavalent DTwP-IPV-HB-PRP∼T vaccine versus separate DTwP-HB-PRP∼T and IPV vaccines at 12-24 months of age and safety and immunogenicity of a booster dose of DTwP-IPV-HB-PRP∼T in healthy infants in IndiaS Mangarule, S Palkar, M Mitra, et al.
Vaccine: X|April 25, 2022
Safety and immunogenicity of a hexavalent DTwP-IPV-HB-PRP∼T vaccine versus separate DTwP-HB-PRP∼T and IPV vaccines in healthy infants in IndiaS Mangarule, S Palkar, M Mitra, et al.
Vaccine|July 24, 2019
Immunogenicity and safety of a liquid Pentavalent (DTwP-Hb-Hib) combination vaccine manufactured by Human Biologicals Institute in 6-8 weeks old healthy infants: A phase III, randomized, single blind, non-inferiority studySai Krishna Susarla, Madhu Gupta, Mukta Mantan, et al.
Vaccine|September 20, 2024
A randomized, active-controlled, multi-centric, phase-II clinical study to assess safety and immunogenicity of a fully liquid DTwP-HepB-IPV-Hib hexavalent vaccine (HEXASIIL®) in Indian toddlersHitt Sharma, Sameer Parekh, Pramod Pujari, et al.
Vaccine|September 4, 2023
Immunogenicity and safety of Havisure<sup>TM</sup> vaccine developed by Human Biologicals Institute in healthy subjects of 12 months to 49 years of age: A phase II/III, randomized, single blind, non-inferiority studySai Krishna Susarla, Madhu Gupta, Kheya Ghosh Uttam, et al.
Vaccine|August 6, 2014
A multicenter prospective hospital-based surveillance to estimate the burden of rotavirus gastroenteritis in children less than five years of age in IndiaT Saluja, S D Sharma, M Gupta, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Indian Pediatrics|November 22, 2000
Pyoderma gangrenosumM D Ravi, N Sanju
Indian Journal of Pediatrics|March 25, 2014
Vaccination Related Pain: Comparison of Two Injection TechniquesG N Girish, M D Ravi
Hospital Pharmacy|September 25, 2024
Chronic Immune Thrombocytopenia Purpura Following COVID-19 Vaccination (ChAdOx1 -nCov-19): A Case Report With OneYear Follow-UpMerrin Mathew, Rovin M Theempalangad, Juny Sebastian, et al.
Intractable & Rare Diseases Research|August 27, 2020
Comprehensive Rare Disease Care model for screening and diagnosis of rare genetic diseases - an experience of private medical college and hospital, South IndiaSathish Raju Nilakantam, Deepa Bhat, M D Ravi, et al.
Vaccine: X|July 28, 2022
Antibody persistence following administration of a hexavalent DTwP-IPV-HB-PRP∼T vaccine versus separate DTwP-HB-PRP∼T and IPV vaccines at 12-24 months of age and safety and immunogenicity of a booster dose of DTwP-IPV-HB-PRP∼T in healthy infants in IndiaS Mangarule, S Palkar, M Mitra, et al.
Vaccine: X|April 25, 2022
Safety and immunogenicity of a hexavalent DTwP-IPV-HB-PRP∼T vaccine versus separate DTwP-HB-PRP∼T and IPV vaccines in healthy infants in IndiaS Mangarule, S Palkar, M Mitra, et al.
Vaccine|July 24, 2019
Immunogenicity and safety of a liquid Pentavalent (DTwP-Hb-Hib) combination vaccine manufactured by Human Biologicals Institute in 6-8 weeks old healthy infants: A phase III, randomized, single blind, non-inferiority studySai Krishna Susarla, Madhu Gupta, Mukta Mantan, et al.
Vaccine|September 20, 2024
A randomized, active-controlled, multi-centric, phase-II clinical study to assess safety and immunogenicity of a fully liquid DTwP-HepB-IPV-Hib hexavalent vaccine (HEXASIIL®) in Indian toddlersHitt Sharma, Sameer Parekh, Pramod Pujari, et al.
Vaccine|September 4, 2023
Immunogenicity and safety of Havisure<sup>TM</sup> vaccine developed by Human Biologicals Institute in healthy subjects of 12 months to 49 years of age: A phase II/III, randomized, single blind, non-inferiority studySai Krishna Susarla, Madhu Gupta, Kheya Ghosh Uttam, et al.
Vaccine|August 6, 2014
A multicenter prospective hospital-based surveillance to estimate the burden of rotavirus gastroenteritis in children less than five years of age in IndiaT Saluja, S D Sharma, M Gupta, et al.
Pageof 2